Infinity Doesn't Sugarcoat Disappointing Duvelisib Data
Executive Summary
Infinity's hopes for accelerated approval of the PI3K inhibitor based on the DYNAMO study have been dashed, so while it plots a new strategy – with or without partner AbbVie – it cuts discovery R&D staff.
You may also be interested in...
Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: DMD, RMAT, HIV, BTDs, Tc-99m – FTW
The latest drug development news and highlights from our US FDA Performance Tracker.